股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國健康科技集團控股有限公司 呈交日期: 2025年11月4日 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01069 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.1 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.1 | HKD | | 100,000,000 | 本月底法定/註冊股 ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號：1069) 2. Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summ ...

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股份代號：1069） 2025 環境、社會及管治報告 | 目錄 | | | | | --- | --- | --- | --- | | 敬啟 | | | 2 | | 關於本報告 | | | 2 | | 可持續發展方針 | | | 3 | | A. | 環境責任 | | 8 | | 層面A1. | | 產生的排放物及廢棄物 | 9 | | 層面A2. | | 資源使用 | 12 | | 層面A3. | | 環境及天然資源 | 13 | | | | 應對氣候變化 | 14 | | B. | 社會責任 | | 17 | | 層面B1. | | 僱傭 | 17 | | 層面B2. | | 僱員健康與工作場所安全 | 21 | | 層面B3. | | 發展及培訓 | 22 | | 層面B4. | | 勞工準則 | 23 | | 層面B5. | | 供應鏈管理 | 23 | | 層面B6. | | 產品責任 | 24 | | 層面B7. | | 反貪污 | 25 | | 層面B8. | | 社區投資 | 26 | | | | 環境關鍵績效指標 | 27 | ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號：1069) NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, China Health Technology Group Holding Company Limited (the "Company") – Notice of publication of Annual Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.01069.com.cn and the website of The Stock Exchange of Hong Kong Limi ...

Financial Performance - For the fiscal year ending June 30, 2025, the company's revenue was approximately RMB 90.2 million, a significant increase from RMB 47.6 million in the fiscal year 2024, representing an increase of 89.5%[9] - The profit attributable to owners for the fiscal year 2025 was approximately RMB 22.7 million, a decrease from RMB 200 million in the fiscal year 2024, indicating a decline of 88.6%[9] - The total comprehensive income attributable to owners for the fiscal year 2025 was approximately RMB 28.2 million, down from RMB 204 million in the fiscal year 2024, reflecting a decrease of 86.1%[9] - The basic earnings per share for the fiscal year 2025 were RMB 2.75, a significant drop from RMB 29.79 in the fiscal year 2024[9] - Gross profit for fiscal year 2025 was approximately RMB 8,200,000, up from RMB 1,900,000 in fiscal year 2024, with a gross margin of 9.1%, compared to 4.0% in the previous year[21] - The company reported a profit before tax of RMB 23,026,000 for the fiscal year ending June 30, 2025, compared to a profit of RMB 200,020,000 in 2024[45] - The company reported a net profit of RMB 22,711,000 for the year, compared to RMB 200,013,000 in the previous year, indicating a decrease due to prior year's debt restructuring gains[156] - Total comprehensive income for the year was RMB 28,216,000, down from RMB 204,049,000 in 2024, primarily due to the absence of debt restructuring income[156] Revenue Sources - The company completed a total timber harvest of approximately 18,016 cubic meters in the fiscal year 2025, generating timber sales revenue of approximately RMB 36.6 million[13] - The company recorded ginseng sales revenue of approximately RMB 14.5 million in the fiscal year 2025, compared to RMB 2.56 million in the fiscal year 2024, marking an increase of 466.4%[16] - The ginseng business generated total revenue of approximately RMB 39.5 million in the fiscal year 2025, including RMB 25 million from purchased ginseng and RMB 14.5 million from self-cultivated ginseng[16] - The health products manufacturing and trading business recorded revenue of approximately RMB 14.1 million in the fiscal year 2025[17] - In the fiscal year 2025, the company generated revenue of approximately RMB 36.6 million from forestry management, RMB 39.5 million from ginseng business, and RMB 14.1 million from health products[55] Capital Structure and Debt - The capital debt ratio as of June 30, 2025, was approximately 77.3%, a decrease of 15.4 percentage points from 92.7% in the fiscal year 2024[9] - As of June 30, 2025, the company had total assets of approximately RMB 205,400,000 and net assets of approximately RMB 46,700,000[28] - The company has no secured bank borrowings as of June 30, 2025[62] - The company reported a decrease in total liabilities, with cumulative losses amounting to RMB 938,993 thousand as of June 30, 2025[161] Shareholder Information - The company did not recommend any dividend distribution for the fiscal year 2025, consistent with the previous fiscal year[9] - As of June 30, 2025, the company has no distributable reserves available for shareholders, consistent with the previous year[75] - The company has issued at least 25% of its shares to the public as of the fiscal year 2025[73] - The company completed a share consolidation on July 8, 2025, reducing the total issued shares from 859,242,204 to 85,924,220[37] - The company raised approximately HKD 5.85 million through a placement of 143,000,000 new shares at HKD 0.043 per share, increasing the issued share capital by about 16.64%[38] Governance and Management - The board consists of six members, including two women, achieving gender diversity with a target to maintain at least one female director[101] - The company has adopted a board diversity policy, considering various factors such as gender, age, cultural background, and professional experience[99] - The board has reviewed the effectiveness of the board diversity policy and the implementation of the employee diversity policy for the fiscal year 2025[102] - The company has established a management authorization framework, allowing management to execute daily operational responsibilities under the CEO's leadership[108] - The board has a structured approach to continuous professional development for its members, ensuring compliance with corporate governance codes[109] Risk Management - The company faced credit risk primarily from receivables, with a significant portion of bank deposits held in high credit-rated banks, minimizing potential losses[70] - The company maintains sufficient cash and cash equivalents to manage liquidity risk and reduce cash flow volatility[71] - The internal control and risk management systems were reviewed by the Board through the Audit Committee, which found no significant deficiencies and confirmed effective implementation during fiscal year 2025[129] Compliance and Reporting - The financial statements have been prepared in accordance with the Hong Kong Financial Reporting Standards and the disclosure requirements of the Hong Kong Companies Ordinance[139] - The auditor's report does not cover other information included in the annual report, which is the responsibility of the company's directors[148] - The company regularly reviews its corporate governance practices to ensure compliance with established codes and regulations[96] Future Outlook - The company plans to gradually reduce reliance on suppliers for aged ginseng by cultivating its own stock, ensuring quality through genetic consistency with supplier plants[18] - The company successfully cultivated its first batch of Epimedium in June 2024 and expanded its planting area by 28 acres in July 2024, with expected sales by June 2026[19] - The group expects that the new and revised Hong Kong Financial Reporting Standards will not have a significant impact on the consolidated financial statements[171]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國健康科技集團控股有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01069 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.1 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.1 HKD | | 100,000,000 | 本月底法定/註冊股本總額： H ...

Core Viewpoint - China Health Technology Group (01069.HK) reported significant revenue growth but a substantial decline in net profit for the fiscal year ending June 30, 2025 [1] Financial Performance - The company's revenue reached RMB 90.215 million, representing a year-on-year increase of 89.50% [1] - The net profit for the year was RMB 22.711 million, a decrease of 88.65% compared to the previous year [1] - Basic earnings per share were RMB 0.0275 [1] Gross Profit and Margin - The group recorded a gross profit of approximately RMB 8.2 million, up from about RMB 1.9 million in the fiscal year 2024 [1] - The gross margin improved to approximately 9.1%, compared to about 4.0% in the previous fiscal year [1] - The increase in gross profit was primarily driven by overall revenue growth, with the higher margin new health product business launched in November 2024 contributing significantly [1]

Group 1 - The core viewpoint of the article is that China Health Technology Group reported significant revenue growth but a substantial decline in profit for the fiscal year ending June 30, 2025 [1] Group 2 - The company's revenue reached approximately 90.2 million, representing a year-on-year increase of 89.5% [1] - The profit attributable to the company's owners was about 22.7 million, showing a year-on-year decrease of 88.65% [1] - The basic earnings per share were reported at 2.75 cents [1]

Core Insights - China Health Technology Group (01069) reported annual results for the year ending June 30, 2025, with revenue of approximately 90.2 million, representing a year-on-year increase of 89.5% [1] - The profit attributable to the company's owners was approximately 22.7 million, reflecting a year-on-year decrease of 88.65% [1] - Basic earnings per share were reported at 2.75 cents [1]

Financial Performance - For the fiscal year ending June 30, 2025, the company's revenue was approximately RMB 90.2 million, a significant increase from RMB 47.6 million in the previous fiscal year[3] - The profit attributable to the owners for the fiscal year 2025 was approximately RMB 22.7 million, down from RMB 200 million in fiscal year 2024[4] - The total comprehensive income attributable to the owners for fiscal year 2025 was approximately RMB 28.2 million, compared to RMB 204 million in fiscal year 2024[4] - Basic earnings per share for fiscal year 2025 were RMB 2.75, a decrease from RMB 29.79 in fiscal year 2024[4] - The company reported a gross profit of RMB 8.2 million for fiscal year 2025, compared to RMB 1.9 million in fiscal year 2024[4] - The group reported a total profit of RMB 30,197,000 for the year ending June 30, 2025, compared to RMB 11,705,000 in the previous year, marking an increase of 157.5%[19] - The company reported a net profit of RMB 22,711,000 for 2025, a significant decrease from RMB 200,013,000 in 2024[31] Revenue Breakdown - Revenue from the timber-related products was RMB 36,633,000, up from RMB 32,521,000, indicating an increase of 34.5% year-over-year[15] - Revenue from ginseng-related products surged to RMB 39,467,000 from RMB 15,085,000, reflecting a growth of 161.5%[15] - The company’s total revenue from external customers in China reached RMB 76,100,000 in 2025, up from RMB 47,606,000 in 2024, an increase of 59.8%[25] - Ginseng business revenue reached approximately RMB 39.5 million in the 2025 fiscal year, with RMB 25 million from supplier purchases and RMB 14.5 million from self-cultivated ginseng[39] - Health product manufacturing and trading business generated revenue of approximately RMB 14.1 million in the 2025 fiscal year[40] Assets and Liabilities - The total assets less current liabilities increased to RMB 162.3 million in fiscal year 2025, up from RMB 128.9 million in fiscal year 2024[5] - The net assets of the company increased to RMB 46.7 million in fiscal year 2025, compared to RMB 12.9 million in fiscal year 2024[6] - Total assets increased to RMB 205,417,000 in 2025 from RMB 178,166,000 in 2024, representing a growth of 15.3%[22] - Total liabilities decreased to RMB 158,697,000 in 2025 from RMB 165,203,000 in 2024, a reduction of 3.1%[22] Capital Structure - The capital-to-debt ratio improved to approximately 77.3% in fiscal year 2025, down from 92.7% in fiscal year 2024, representing a decrease of 15.4 percentage points[3] - The capital-to-debt ratio as of June 30, 2025, was approximately 77.3%, a decrease from 92.7% as of June 30, 2024[57] Dividends and Share Structure - The company did not recommend any dividend distribution for fiscal year 2025, consistent with fiscal year 2024[3] - No final dividend has been recommended for the fiscal year 2025, consistent with the previous fiscal year[64] - A share consolidation was approved on July 4, 2025, reducing the total number of issued shares from 859,242,204 to 85,924,220[60] - The total number of issued shares has been adjusted from 859,242,204 to 85,924,220 following the share consolidation effective July 8, 2025[62] - The company announced a conditional placement of up to 17,000,000 new shares at a price of HKD 0.28 per share, aiming to raise approximately HKD 4.63 million, which represents an increase of about 16.52% in the enlarged issued share capital[63] Operational Developments - The company began operations in the health product trading business in November 2024, indicating a strategic expansion into new markets[8] - The group obtained harvesting permits for 18,016 cubic meters for the 2025 calendar year, an increase from the previous year's harvesting volume[41] - The group plans to gradually reduce reliance on suppliers for aged ginseng as it builds sufficient inventory of self-cultivated ginseng[41] - The group successfully planted the first batch of Epimedium on its owned land in June 2024, with an additional 28 acres planted in July 2024[42] Financial Reporting Standards - The group anticipates the adoption of new Hong Kong Financial Reporting Standards will impact its accounting policies starting from the first period after their effective date[13] - The new Hong Kong Financial Reporting Standard No. 18 will introduce new presentation and disclosure requirements in the consolidated income statement, effective from January 1, 2027[13] - The group is currently assessing the detailed impact of the new standards on its consolidated financial statements[13] - The group expects that other amendments to the Hong Kong Financial Reporting Standards will not have a significant impact on its consolidated financial statements[13] Expenses and Costs - Administrative expenses decreased by approximately 27.0% to RMB 15.7 million in fiscal year 2025, down from RMB 21.5 million in fiscal year 2024, mainly due to a reduction in legal expenses[47] - Financing costs increased by approximately 8.5% to RMB 3.5 million in fiscal year 2025, compared to RMB 3.2 million in fiscal year 2024[49] - The company incurred a total cost of RMB 36,633,000 for harvested timber in 2025, compared to RMB 32,522,000 in 2024, an increase of 12.9%[29] Trade Receivables and Payables - Trade receivables increased to RMB 33,796,000 in 2025 from RMB 17,343,000 in 2024, representing a growth of 95.5%[32] - Trade payables increased to RMB 29,029,000 in 2025 from RMB 16,304,000 in 2024, reflecting a growth of 77.6%[32] - The average credit period granted to trade customers remains at 120 days for both 2024 and 2025[32] - The average credit period for purchasing goods is maintained at 90 days[32] Audit and Compliance - The audit committee, consisting of three independent non-executive directors, reviewed the financial reporting process and internal control systems, and has no objections to the group's consolidated financial performance as reported[71]